Display options
Cite
Lin CC, Fang C, Benetton S, et al. Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrob Agents Chemother. 2006;50(9):2926-31doi: 10.1128/AAC.01566-05.
Lin, C. C., Fang, C., Benetton, S., Xu, G. F., & Yeh, L. T. (2006). Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrobial agents and chemotherapy, 50(9), 2926-31. https://doi.org/10.1128/AAC.01566-05
Lin, Chin-chung, et al. "Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer." Antimicrobial agents and chemotherapy vol. 50,9 (2006): 2926-31. doi: https://doi.org/10.1128/AAC.01566-05
Lin CC, Fang C, Benetton S, Xu GF, Yeh LT. Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrob Agents Chemother. 2006 Sep;50(9):2926-31. doi: 10.1128/AAC.01566-05. PMID: 16940083; PMCID: PMC1563525.
Copy Download .nbib Format: NLM
Share it on

Antimicrob Agents Chemother. 2006 Sep;50(9):2926-31. doi: 10.1128/AAC.01566-05.

Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer.

Antimicrobial agents and chemotherapy

Chin-chung Lin, Che Fang, Salete Benetton, Gui-fen Xu, Li-Tain Yeh

Affiliations

  1. Drug Development, Valeant Research & Development, Costa Mesa, CA 92626, USA. [email protected]

PMID: 16940083 PMCID: PMC1563525 DOI: 10.1128/AAC.01566-05

Abstract

Metabolic activation of pradefovir to 9-(2-phosphonylmethoxyethyl)adenine (PMEA) was evaluated by using cDNA-expressed CYP isozymes in portal vein-cannulated rats following oral administration and in human liver microsomes. The enzyme induction potential of pradefovir was evaluated in rats following multiple oral dosing and in primary cultures of human hepatocytes. The results indicated that CYP3A4 is the only cDNA-expressed CYP isozyme catalyzing the conversion of pradefovir to PMEA. Pradefovir was converted to PMEA in human liver microsomes with a K(m) of 60 microM, a maximum rate of metabolism of 228 pmol/min/mg protein, and an intrinsic clearance of about 359 ml/min. Addition of ketoconazole and monoclonal antibody 3A4 significantly inhibits the conversion of pradefovir to PMEA in human liver microsomes, suggesting the predominant role of CYP3A4 in the metabolic activation of pradefovir. Pradefovir at 0.2, 2, and 20 microM was neither a direct inhibitor nor a mechanism-based inhibitor of CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP2E1, and CYP1A2 in human liver microsomes. In rats, the liver was the site of metabolic activation of pradefovir, whereas the small intestine did not play a significant role in the metabolic conversion of pradefovir to PMEA. Daily oral dosing (300 mg/kg of body weight) to rats for 8 days showed that pradefovir was not an inducer of P450 enzymes in rats. Furthermore, pradefovir at 10 microg/ml was not an inducer of either CYP1A2 or CYP3A4/5 in primary cultures of human hepatocytes.

References

  1. N Engl J Med. 2003 Feb 27;348(9):808-16 - PubMed
  2. J Clin Pharmacol. 2005 Nov;45(11):1250-8 - PubMed
  3. Drug Metab Dispos. 2003 Jul;31(7):815-32 - PubMed
  4. Neoplasma. 1990;37(2):111-20 - PubMed
  5. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1499-503 - PubMed
  6. Antiviral Res. 1991 Jul;16(1):115-9 - PubMed
  7. Antiviral Res. 1993 Jun;21(2):141-53 - PubMed
  8. Antimicrob Agents Chemother. 1994 Feb;38(2):365-8 - PubMed
  9. Antimicrob Agents Chemother. 1994 Sep;38(9):2180-2 - PubMed
  10. N Engl J Med. 2003 Feb 27;348(9):800-7 - PubMed
  11. Antimicrob Agents Chemother. 1995 Nov;39(11):2401-5 - PubMed
  12. Drug Metab Dispos. 1997 Mar;25(3):362-6 - PubMed
  13. Ther Drug Monit. 1997 Aug;19(4):436-45 - PubMed
  14. J Pharmacol Exp Ther. 1997 Dec;283(3):1552-62 - PubMed
  15. Drug Metab Dispos. 1999 Feb;27(2):180-7 - PubMed
  16. Antivir Chem Chemother. 2004 Nov;15(6):307-17 - PubMed
  17. Antimicrob Agents Chemother. 2005 Mar;49(3):925-30 - PubMed
  18. Biol Pharm Bull. 2003 May;26(5):695-700 - PubMed

Substances

MeSH terms

Publication Types